Date: 2012-05-22
Type of information: Grant
Company: Prothix (The Netherlands), Bioceros (The Netherlands), Antitope (UK),The University Medical Center of Utrecht (The Netherlands)
Investors: Eureka Eurostars program
Amount: €1.6 million
Funding type: grant
Planned used: The grant has been awarded for the pre-clinical development of a monoclonal antibody as a novel anticoagulant with a favorable benefit to risk ratio.
Others: Prothix BV and Bioceros BV, University Medical Center Utrecht (UMCU, the Netherlands) and UK biotech company Antitope have been awarded a grant within Eureka’s Eurostars™ program with a total budget of over €1.6 million.
Therapeutic area:
